title: Nandrolone treatment decreases the level of rat kidney alpha(1B)-adrenoceptors.
abstract: Abuse of anabolic androgenic steroids (AAS) is associated with serious side effects, such as hypertension and fluid retention. Renal alpha(1)- and alpha(2)-adrenoceptors are implicated in the regulation of blood pressure and fluid balance. In the present study, the levels of renal alpha(1A)-, alpha(1B)-, alpha(2A)- and alpha(2B)-adrenoceptors, and spleen alpha(1B)-adrenoceptors, were quantified in tissue membranes from rats treated with the AAS nandrolone decanoate (15 mg/kg) for 14 days. The radioligands used were [(3)H]-prazosin and [(3)H]-RX821002. The nandrolone treatment caused a 50% reduction of kidney alpha(1B)-adrenoceptors (from 15 fmol/mg protein in control rats to 6.5 fmol/mg protein in treated rats). In contrast, the levels of kidney alpha(1A)-, alpha(2A)- and alpha(2B)-, and spleen alpha(1B)-adrenoceptors were unaffected. These results raise the possibility that a decreased level of kidney alpha(1B)-adrenoceptors may cause some of the effects observed on blood pressure and fluid balance in heavy abuse of AAS.
authors.affiliation: Department of Pharmaceutical Biosciences, Uppsala University, Box 591 BioMedical Centre, 751 24 Uppsala, Sweden.
authors.forename: Staffan
authors.initials: S
authors.lastname: Uhlén
authors.forename: Jonas
authors.initials: J
authors.lastname: Lindblom
authors.forename: Anna
authors.initials: A
authors.lastname: Kindlundh
authors.forename: Paul
authors.initials: P
authors.lastname: Mugisha
authors.forename: Fred
authors.initials: F
authors.lastname: Nyberg
mesh_terms: D058668:Adrenergic alpha-1 Receptor Antagonists; D058669:Adrenergic alpha-2 Receptor Antagonists; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D045930:Anabolic Agents / Q000494:pharmacology*; D000818:Animals; D019329:Idazoxan / Q000031:analogs & derivatives* / Q000494:pharmacology; D007273:Injections, Intramuscular; D007668:Kidney / Q000187:drug effects* / Q000378:metabolism; D008024:Ligands; D008297:Male; D009277:Nandrolone / Q000494:pharmacology*; D011224:Prazosin / Q000494:pharmacology; D011869:Radioligand Assay; D051381:Rats; D017207:Rats, Sprague-Dawley; D018340:Receptors, Adrenergic, alpha-1 / Q000096:biosynthesis*; D018341:Receptors, Adrenergic, alpha-2 / Q000096:biosynthesis; D013154:Spleen / Q000187:drug effects / Q000378:metabolism
chemical_list: C547718:Adra1b protein, rat; C547770:Adra2a protein, rat; C547773:Adra2b protein, rat; D058668:Adrenergic alpha-1 Receptor Antagonists; D058669:Adrenergic alpha-2 Receptor Antagonists; D000317:Adrenergic alpha-Antagonists; D045930:Anabolic Agents; D008024:Ligands; D018340:Receptors, Adrenergic, alpha-1; D018341:Receptors, Adrenergic, alpha-2; D009277:Nandrolone; C058525:2-methoxyidazoxan; D011224:Prazosin; D019329:Idazoxan